ROIVANT SCIENCES LTD (ROIV) Stock Fundamental Analysis

NASDAQ:ROIV • BMG762791017

26.45 USD
-0.3 (-1.12%)
At close: Feb 13, 2026
26.92 USD
+0.47 (+1.78%)
After Hours: 2/13/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

ROIV gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 523 industry peers in the Biotechnology industry. While ROIV has a great health rating, there are worries on its profitability. While showing a medium growth rate, ROIV is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • ROIV had negative earnings in the past year.
  • ROIV had a negative operating cash flow in the past year.
  • In the past 5 years ROIV reported 4 times negative net income.
  • ROIV had a negative operating cash flow in each of the past 5 years.
ROIV Yearly Net Income VS EBIT VS OCF VS FCFROIV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 0 1B -1B 2B 3B 4B

1.2 Ratios

  • ROIV has a Return On Assets of -7.39%. This is amongst the best in the industry. ROIV outperforms 85.85% of its industry peers.
  • The Return On Equity of ROIV (-8.57%) is better than 88.53% of its industry peers.
Industry RankSector Rank
ROA -7.39%
ROE -8.57%
ROIC N/A
ROA(3y)4.94%
ROA(5y)-9.82%
ROE(3y)-5.99%
ROE(5y)-22.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROIV Yearly ROA, ROE, ROICROIV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 50 -50

1.3 Margins

  • ROIV's Gross Margin of 96.41% is amongst the best of the industry. ROIV outperforms 96.37% of its industry peers.
  • In the last couple of years the Gross Margin of ROIV has remained more or less at the same level.
  • ROIV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.41%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.96%
GM growth 5Y-0.3%
ROIV Yearly Profit, Operating, Gross MarginsROIV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 5K 10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. Health

2.1 Basic Checks

  • ROIV does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ROIV has less shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, ROIV has more shares outstanding
  • ROIV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ROIV Yearly Shares OutstandingROIV Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M
ROIV Yearly Total Debt VS Total AssetsROIV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 2B 4B 6B

2.2 Solvency

  • ROIV has an Altman-Z score of 16.11. This indicates that ROIV is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 16.11, ROIV belongs to the top of the industry, outperforming 87.57% of the companies in the same industry.
  • ROIV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 16.11
ROIC/WACCN/A
WACC9.24%
ROIV Yearly LT Debt VS Equity VS FCFROIV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 2B 4B

2.3 Liquidity

  • A Current Ratio of 33.70 indicates that ROIV has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 33.70, ROIV belongs to the top of the industry, outperforming 98.28% of the companies in the same industry.
  • A Quick Ratio of 33.70 indicates that ROIV has no problem at all paying its short term obligations.
  • The Quick ratio of ROIV (33.70) is better than 98.28% of its industry peers.
Industry RankSector Rank
Current Ratio 33.7
Quick Ratio 33.7
ROIV Yearly Current Assets VS Current LiabilitesROIV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 2B 4B 6B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • ROIV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.65%, which is quite good.
  • Looking at the last year, ROIV shows a very negative growth in Revenue. The Revenue has decreased by -74.11% in the last year.
  • ROIV shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -15.56% yearly.
EPS 1Y (TTM)17.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.16%
Revenue 1Y (TTM)-74.11%
Revenue growth 3Y-19.3%
Revenue growth 5Y-15.56%
Sales Q2Q%-64.89%

3.2 Future

  • ROIV is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 59.18% yearly.
  • Based on estimates for the next years, ROIV will show a very strong growth in Revenue. The Revenue will grow by 108.17% on average per year.
EPS Next Y-413.26%
EPS Next 2Y-132.67%
EPS Next 3Y-44.09%
EPS Next 5Y59.18%
Revenue Next Year-80.14%
Revenue Next 2Y29.27%
Revenue Next 3Y119.16%
Revenue Next 5Y108.17%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ROIV Yearly Revenue VS EstimatesROIV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2B 4B 6B
ROIV Yearly EPS VS EstimatesROIV Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 4

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ROIV. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ROIV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ROIV Price Earnings VS Forward Price EarningsROIV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ROIV Per share dataROIV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • A cheap valuation may be justified as ROIV's earnings are expected to decrease with -44.09% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-132.67%
EPS Next 3Y-44.09%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ROIV does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ROIVANT SCIENCES LTD

NASDAQ:ROIV (2/13/2026, 8:00:01 PM)

After market: 26.92 +0.47 (+1.78%)

26.45

-0.3 (-1.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)N/A
Inst Owners65.11%
Inst Owner ChangeN/A
Ins Owners3.84%
Ins Owner Change-1.85%
Market Cap18.40B
Revenue(TTM)20.33M
Net Income(TTM)-373.97M
Analysts85.56
Price Target27.26 (3.06%)
Short Float %5.38%
Short Ratio3.58
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)22.89%
Min EPS beat(2)-4.36%
Max EPS beat(2)50.15%
EPS beat(4)3
Avg EPS beat(4)58.4%
Min EPS beat(4)-4.36%
Max EPS beat(4)180.12%
EPS beat(8)6
Avg EPS beat(8)50.87%
EPS beat(12)7
Avg EPS beat(12)31.34%
EPS beat(16)9
Avg EPS beat(16)18.02%
Revenue beat(2)0
Avg Revenue beat(2)-74.21%
Min Revenue beat(2)-77.83%
Max Revenue beat(2)-70.59%
Revenue beat(4)0
Avg Revenue beat(4)-64.48%
Min Revenue beat(4)-86.28%
Max Revenue beat(4)-23.24%
Revenue beat(8)2
Avg Revenue beat(8)-34.24%
Revenue beat(12)5
Avg Revenue beat(12)-18.03%
Revenue beat(16)7
Avg Revenue beat(16)-4.01%
PT rev (1m)3.16%
PT rev (3m)36.02%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.38%
EPS NY rev (1m)0%
EPS NY rev (3m)11.76%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-9.25%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-18.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 904.9
P/FCF N/A
P/OCF N/A
P/B 4.22
P/tB 4.22
EV/EBITDA N/A
EPS(TTM)-0.56
EYN/A
EPS(NY)-1.35
Fwd EYN/A
FCF(TTM)-1.13
FCFYN/A
OCF(TTM)-1.11
OCFYN/A
SpS0.03
BVpS6.27
TBVpS6.27
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -7.39%
ROE -8.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.41%
FCFM N/A
ROA(3y)4.94%
ROA(5y)-9.82%
ROE(3y)-5.99%
ROE(5y)-22.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.96%
GM growth 5Y-0.3%
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 228.14%
Cap/Sales 71.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 33.7
Quick Ratio 33.7
Altman-Z 16.11
F-Score4
WACC9.24%
ROIC/WACCN/A
Cap/Depr(3y)35.38%
Cap/Depr(5y)N/A
Cap/Sales(3y)13.59%
Cap/Sales(5y)19.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.16%
EPS Next Y-413.26%
EPS Next 2Y-132.67%
EPS Next 3Y-44.09%
EPS Next 5Y59.18%
Revenue 1Y (TTM)-74.11%
Revenue growth 3Y-19.3%
Revenue growth 5Y-15.56%
Sales Q2Q%-64.89%
Revenue Next Year-80.14%
Revenue Next 2Y29.27%
Revenue Next 3Y119.16%
Revenue Next 5Y108.17%
EBIT growth 1Y-3.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-16.51%
EBIT Next 3Y-0.33%
EBIT Next 5YN/A
FCF growth 1Y7.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.22%
OCF growth 3YN/A
OCF growth 5YN/A

ROIVANT SCIENCES LTD / ROIV FAQ

What is the ChartMill fundamental rating of ROIVANT SCIENCES LTD (ROIV) stock?

ChartMill assigns a fundamental rating of 4 / 10 to ROIV.


What is the valuation status for ROIV stock?

ChartMill assigns a valuation rating of 0 / 10 to ROIVANT SCIENCES LTD (ROIV). This can be considered as Overvalued.


How profitable is ROIVANT SCIENCES LTD (ROIV) stock?

ROIVANT SCIENCES LTD (ROIV) has a profitability rating of 3 / 10.


What is the earnings growth outlook for ROIVANT SCIENCES LTD?

The Earnings per Share (EPS) of ROIVANT SCIENCES LTD (ROIV) is expected to decline by -413.26% in the next year.